rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
2
|
pubmed:dateCreated |
2008-1-10
|
pubmed:abstractText |
This study investigated the long-term outcome of patients with tuberculosis (TB) as a complication of tumour necrosis factor (TNF)-alpha blocker therapy. All TB cases (n = 21) complicating TNF-alpha blocker therapy from French university hospitals were collated between January 2000 and September 2002. Outcome was assessed via a postal questionnaire during September 2005. The mortality rate after 4 years was 4.8%, and one patient had relapsed and six (29%) patients had recommenced TNF-alpha antagonist treatment, after appropriate anti-TB therapy, without reactivation. These data support the concept that TNF-alpha antagonists can be restarted in TB patients provided that adequate anti-TB treatment has been completed.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1198-743X
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
14
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
183-6
|
pubmed:meshHeading |
pubmed-meshheading:18076664-Aged,
pubmed-meshheading:18076664-Aged, 80 and over,
pubmed-meshheading:18076664-Antibodies, Monoclonal,
pubmed-meshheading:18076664-Antirheumatic Agents,
pubmed-meshheading:18076664-Antitubercular Agents,
pubmed-meshheading:18076664-Arthritis, Rheumatoid,
pubmed-meshheading:18076664-Female,
pubmed-meshheading:18076664-Follow-Up Studies,
pubmed-meshheading:18076664-France,
pubmed-meshheading:18076664-Humans,
pubmed-meshheading:18076664-Immunosuppressive Agents,
pubmed-meshheading:18076664-Male,
pubmed-meshheading:18076664-Middle Aged,
pubmed-meshheading:18076664-Questionnaires,
pubmed-meshheading:18076664-Treatment Outcome,
pubmed-meshheading:18076664-Tuberculosis,
pubmed-meshheading:18076664-Tumor Necrosis Factor-alpha
|
pubmed:year |
2008
|
pubmed:articleTitle |
Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment.
|
pubmed:affiliation |
Université Paris V, Hôpital Necker-Enfants Malades, Service des Maladies Infectieuses et Tropicales, Centre d'Infectiologie Necker-Pasteur, Paris, France.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|